Roles and Responsibilities of a 340B Coordinator
The 340B Drug Pricing Program operates inside one of the most complex regulatory environments in American healthcare. HRSA publishes the governing requirements. GAO audits the results. The gap between what the program requires and what a covered entity actually delivers is where 340B coordinator services live.
The 340B compliance coordinator is the operational linchpin of a compliant 340B program. They are responsible for eligibility, diversion prevention, duplicate discount avoidance, database accuracy, contract pharmacy oversight, and recordkeeping. HRSA has audited 200 covered entities per year since 2012, and any entity that does not comply may be held liable for refunds of the discounts obtained.
Here, we explain what 340B program administration services cover. You will also learn how a coordinator’s responsibilities differ across covered entity types. We will also understand why specialized support is essential for the most technically demanding areas of the program.
Why Work with a 340B Coordinator?
The 340B program was established under Section 340B of the Public Health Service Act. The program helps covered entities stretch scarce federal resources and reach more eligible patients.
Manufacturers participating in Medicaid agree to provide outpatient drugs to covered entities at significantly reduced prices. This margin funds expanded patient care. But that margin is contingent on compliance; HRSA is explicit that covered entities must meet all program requirements to purchase at 340B prices.
HRSA's Compliance Improvement Guide identifies four strategic pillars a well-functioning 340B program must sustain. These are:
Leadership commitment
Education and training
Integrated 340B systems
Measurable improvement.
None of them can be achieved without a 340B coordinator.
The Scale of the 340B Compliance Obligation
As of 2024, more than 53,000 care sites affiliated with nearly 42,000 covered entities participate in the program. HRSA's 200 annual audits have found non-compliance in a significant share of entities, including diversion and duplicate-discount violations.
A covered entity without a clearly designated coordinator function carries materially higher audit risk. HRSA recommends a dedicated compliance team and an organizational chart that prevents silo management.
340B compliance is not a pharmacy-only function. Section 340B sits at the intersection of pharmacy, finance, compliance, IT, and clinical operations.
340B Coordinator Service Responsibilities in Pharmacy and Program Administration
HRSA specifies five core program requirements every covered entity must meet. The 340B coordinator manages compliance with all five.
1. Maintaining Accurate OPAIS Records
Every covered entity must keep its HRSA Office of Pharmacy Affairs Information System (OPAIS) record accurate. The record should include all outpatient facilities and contract pharmacies.
The 340B program coordinator:
Registers new outpatient and child sites, and all contract pharmacy locations.
Updates records immediately when eligibility, site locations, or contract arrangements change.
Audits the OPAIS record regularly for accuracy.
Manages annual recertification and submits attestations for the authorizing official.
2. Preventing Diversion to Ineligible Patients
340B drugs cannot be sold or transferred to persons not eligible to receive them. It is one of HRSA’s two main audit areas and a consistent Government Accountability Office (GAO) risk finding. Patient eligibility under HRSA requires that the entity provide:
Health care services
An established provider-patient relationship
A provider responsible for the care of the patient.
The 340B coordinator:
Maintains written eligibility policies for every site and care setting
Integrates eligibility criteria into split-billing software to flag ineligible transactions
Conducts regular self-audits of dispensing and administration records
Trains pharmacy, clinical, and billing staff on the patient definition
Manages referral documentation for outside-provider patients
HRSA identifies monthly self-auditing as a leading diversion-prevention practice.
3. Preventing Duplicate Discounts
Covered entities cannot let a drug benefit from both 340B drug pricing and a Medicaid rebate. GAO has repeatedly flagged this as a weak spot. In its most recent report, GAO found HRSA audits don't fully assess Medicaid managed-care compliance, even though most Medicaid prescriptions run through managed care.
The program coordinator:
Maintains the entity's Medicaid Exclusion File (MEF) in OPAIS, reflecting carve-in/carve-out billing status for every site
Coordinates with the state Medicaid agency on duplicate-discount procedures
Builds billing controls preventing 340B drugs from being submitted for rebates
Audits billing against purchase records ahead of external audits
4. Audit Readiness and Recordkeeping
HRSA requires auditable records for every compliance area, and manufacturers can audit entities directly; non-compliant entities may owe refunds.
The 340B coordinator:
Maintains NDC-specific purchase information from ordering to dispensing and billing
Undertakes self-audit process on issues of eligibility, diversion, duplicate discounting, contract pharmacy, and inventory
Corrective action planning
External audit coordination and utilization of HRSA self-disclosure mechanism
5. Contract Pharmacy Oversight
Conditions of the contract pharmacy agreement issued in the final notice in March 2010 by HRSA have to be registered in OPAIS.
The 340B program coordinator ensures that the contract pharmacies operate in accordance with the guidelines of the program through:
Establishment and maintenance of the written agreement between the covered entity and contract pharmacies.
Registration of all contract pharmacy locations with HRSA OPAIS and keeping them updated in case of any changes in the locations.
Implementation of patient eligibility criteria at the contract pharmacy.
Conducting independent audits of contract pharmacies to ensure compliance with patient eligibility, diversion prevention, and duplicate discount criteria.
340B Drug Pricing Management: Purchasing, Inventory, and Split-Billing
Beyond the five core requirements, the 340B coordinator oversees purchasing, inventory, and split-billing operations.
Purchasing Account Configuration
Covered entities must notify drug manufacturers and wholesalers that they are purchasing outpatient drugs at 340B prices. Wholesalers and manufacturers then verify enrollment in OPAIS and sell drugs at or below the ceiling price. The coordinator:
Manages the purchasing account structure
Ensures that 340B-eligible acquisitions are made through compliant accounts and that non-340B purchases are clearly separated.
For covered entities subject to the Group Purchasing Organization (GPO) prohibition, the coordinator must also ensure that 340B drugs are not acquired through a GPO for covered outpatient drugs. These entities are:
Disproportionate share hospitals
Freestanding cancer hospitals
Children's hospitals
Managing the boundary between GPO and non-GPO purchasing requires careful account structure and regular auditing. This is an essential part of 340B drug pricing management.
Split-Billing Software Maintenance
Split-billing software is the operational core of 340B drug pricing management in hospital and multi-site settings. It determines, at the transaction level, which drug purchases qualify for 340B pricing based on patient eligibility, and routes those purchases through the correct acquisition channel.
The HRSA Compliance Improvement Guide identifies split-billing software maintenance as a specific area requiring ongoing attention. The 340B coordinator has to:
Configure the software to reflect current patient eligibility criteria
Maintain NDC crosswalks so that new drug codes are correctly identified
Audit the software's output against dispensing and billing records to catch configuration errors before they create compliance exposure.
340B Ceiling Price Verification
The 340B ceiling price is based on Average Manufacturer Price (AMP) and Unit Rebate Amount (URA).
340B ceiling price= AMP-URA |
The price is then adjusted by package and case size, under the formula published by HRSA.
The coordinator:
Monitors purchase prices against the published ceiling to identify potential manufacturer overcharges
Manages the process of reporting overcharges to HRSA and requesting refunds where applicable.
340B Compliance Coordinator Responsibilities: Education, Training, and Policies
HRSA's Compliance Improvement Guide identifies education and training as one of four strategic pillars of 340B compliance. This is not a one-time orientation exercise. It is an ongoing organizational responsibility that the 340B compliance coordinator manages continuously.
Staff Knowledge Requirements
As per HRSA’s Compliance Improvement Guide, 340B compliance involves the following kinds of knowledge for different positions within an organization:
Organizational leaders need to understand how the program impacts financial goals, legal and regulatory requirements, and risk management.
Operational management staff need working knowledge of drug procurement, inventory management, patient eligibility determination, and billing.
Departmental leaders need to understand provider and staff requirements in their areas.
Frontline staff, including temporary and contract personnel, must be able to carry out the policies and procedures applicable to their roles.
Contract pharmacy staff require training equivalent to internal staff for the functions they perform.
An experienced 340B coordinator:
Identifies the employees under each category
Finds out what knowledge they require
Prepares a training schedule
Policy and Procedure Development and Maintenance
HRSA requires that covered entities maintain comprehensive policies and procedures for all facets of the 340B program. According to HRSA's February 2016 program update, policies and procedures provide guidelines for decisions and actions within a covered entity that promote compliance with the statute, guidance, and policy requirements, while standardizing practices throughout the organization. They should include methodologies for routine self-auditing and internal corrective action.
The 340B compliance coordinator has to:
Develop written policies and procedures. These should cover every operational area:
Procurement
Inventory
Patient eligibility, billing, contract pharmacy, and audit response.
Review and update policies whenever HRSA publishes new guidance, program updates, or policy releases.
Ensure that policies are specific to the covered entity's own settings and workflows, not adapted from generic templates.
Train staff on updated policies when changes are made.
Maintain accessible copies of all policies and procedures for staff reference and audit review.
340B Program Administration: The Coordinator's Role in Organizational Governance
Proper 340B administration cannot be handled by the pharmacy department alone. According to the Compliance Improvement Guide of HRSA, it must be taken up at the organizational level where there is integration across both vertical and horizontal levels. It cannot be confined to the pharmacy department alone. The 340B Coordinator acts as the link between all these functions.
The Authorizing Official and Primary Contact
HRSA requires each covered entity to designate an Authorizing Official who attests to program compliance during registration and annual recertification. The Authorizing Official is a senior organizational leader, typically the Chief Executive Officer or equivalent, who takes formal responsibility for the entity's 340B compliance.
The 340B coordinator supports the Authorizing Official by maintaining the OPAIS record, preparing recertification documentation, and providing regular program status reports.
HRSA also requires each covered entity to designate a Primary Contact for program communications. The coordinator often serves in this capacity, receiving HRSA notices, manufacturer communications, and audit correspondence on behalf of the entity.
Integrating 340B Compliance with Quality and Risk Management
HRSA's Compliance Improvement Guide recommends integrating 340B compliance with the entity's existing quality improvement and risk management frameworks.
Best-practice covered entities:
Have a pharmacy representative on the compliance committee
Submit 340B program metrics to senior management and the Board of Directors quarterly
Integrate 340B compliance risks into all business development and service expansion initiatives.
The 340B coordinator serves as the designated expert who informs those governance processes. They:
Ensure that program requirements influence entity decisions
Notify leadership when there are changes in HRSA policy or GAO audit findings that impact the entity's risks
Ensure that all new services or sites are evaluated from a 340B compliance perspective.
Keeping Pace with a Changing Regulatory Environment
The 340B program does not stay static. HRSA publishes program updates, policy releases, and Federal Register notices that affect covered entity obligations. GAO continues to issue reports identifying compliance weaknesses and recommending policy changes. HRSA has implemented 15 of 20 GAO recommendations since 2011, with additional changes still in progress.
Manufacturer pricing restrictions have introduced new complexities in contract pharmacy and specialty drug purchasing. The 340B Rebate Model Pilot Program, announced by HRSA in July 2026 in the Federal Register, introduced a new rebate mechanism that covered entities must understand and respond to.
The 340B coordinator is responsible for monitoring these developments, assessing their impact on the entity's operations, and updating policies, systems, and staff training accordingly. That ongoing monitoring function is not a project. It is a permanent operational responsibility.
340B Coordination for Orphan Drug Revenue: A Specialty Within a Specialty
For CAHs, SCHs, RRCs, and Freestanding Cancer Centers, the 340B coordinator's standard responsibilities do not include the one area that generates the largest untapped revenue opportunity: orphan drug discretionary pricing. That requires dedicated, manufacturer-specific expertise that falls outside standard program administration.
340B Orphan Drug Solutions works alongside your existing 340B program to close the orphan drug savings gap. We offer a free 30-minute orphan drug revenue assessment exclusively for CAHs, SCHs, and RRCs.
